QuantHealth Gains Strategic Investment, Extending Series A to $17M for Advancing AI-Powered Clinical Trial Simulations.
QuantHealth specializes in revolutionizing clinical trial design with its AI simulation platform.
Company Name: QuantHealth
Location: Tel Aviv, Israel
Sector: AI-Powered Clinical Trial Design
Funding Details: Received strategic investment from Accenture Ventures, a CRO firm, and additional investors. This extends their recent $15M Series A funding round (co-led by Bertelsmann Investments and Pitango HealthTech, with participation from Shoni Top Ventures and Nina Capital) to $17M.
Purpose of Investment: To enhance QuantHealth’s AI simulation platform for clinical trial design.
Leadership: Co-Founder and CEO Orr Inbar
Product: An AI-powered platform for simulating clinical trials, featuring the newly launched product, Katina. This platform uses AI technology trained on extensive datasets to predict trial outcomes and optimize trial protocols.
About Company: QuantHealth specializes in revolutionizing clinical trial design with its AI simulation platform. With proprietary AI technology trained on datasets of 350 million patients, biomedical knowledge-graphs, and clinical trial data, the platform boasts an 86 percent accuracy in predicting trial outcomes.
Key Features:
- Ability to test thousands of protocol variations.
- Discovery of optimal trial designs for success.
- AI-guided workflow in Katina, simulating vast combinations of trial protocols.
Global Partnerships: Collaborating with several global pharmaceutical companies for clinical trial design and development.
